Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19

Dorien Feyaerts(Stanford University), David R. McIlwain(Stanford University), Kazuo Ando(Stanford University), Eileen S. Tsai(Stanford University), Zachary B. Bjornson-Hooper(Stanford University), Justin Meyerowitz(Stanford University), Martin S. Angst(Stanford University), Danielle R. Jacobsen(Stanford University), Dyani Gaudillière(Stanford University), Laura S. Peterson(Stanford University), Sizun Jiang(Beth Israel Deaconess Medical Center), Kari C. Nadeau(Stanford University), Nilanjan Mukherjee(Stanford University), Nima Aghaeepour(Stanford University), Xiaoyuan Han(University of the Pacific), Garry P. Nolan(SRI International), Brice Gaudillière(Stanford Medicine), Evan Do(Stanford University), Sergio Fragoso Saavedra(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Richard Wittman(Stanford University), Theo T. Snow(Stanford University), Benjamin A. Pinsky(Stanford University), Scott D. Boyd(Stanford Medicine), Gopal Krishna Dhondalay(Stanford Medicine), David Furman(Buck Institute for Research on Aging), Monali Manohar(Stanford Medicine), J. Daniel Kelly(University of California, San Francisco), Franck Verdonk(Institut Pasteur), Kristen K. Rumer(Stanford University), Maja Artandi(Stanford University), Julien Hédou(Stanford University), Amy S. Tsai(Stanford Medicine), Iris Chang(Stanford University), Sergio Iván Valdés‐Ferrer(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Christopher Warren(Rutgers, The State University of New Jersey), Edward A. Ganio(Stanford Medicine), Jessica Fitzpatrick(Stanford Medicine), Ina A. Stelzer(Universität Hamburg), R. Sharon Chinthrajah(Johns Hopkins University), Han Chen(Sichuan University), Joshua Gillard(Radboud University Nijmegen)
Cell Reports Medicine
June 28, 2022
Cited by 71


Related Papers